§ Alexander, C.M., Landsman, P.B., Teutsch, S.M. & Haffner, S.M. (2003). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52, 1210–1214.
§ Alexander, H. & Glassman, M.D. (2005). Schizophrenia, antipsychotic drugs, and cardiovascular disease. Journal of Clinical Psychiatry, 66, 5–10.
§ Alexopoulos, G.S., Streim, J., Carpenter, D. & Docherty, J.P. (2004). Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. Journal of Clinical Psychiatry, 65, 5-99.
§ Alvarez-Jiménez, M., González-Blanch, C., Cespo-Facorro, B., Hetrick, S., Rodríguez-Sánchez, J.M., Pérez-Iglesias, R. & Vázquez-Barquero, J.L. (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs, 22(7), 547-62.
§ Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18, 249-55
§ Ballard, C., Creese, B., Corbett, A. & Aarsland, D. (2011, januari). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10(1), 35-43.
§ Bayingana, K., Demarest, S., Gisle, L., Hesse, E., Miermans, P.J., Tafforeau, J., Van der Heyden, J. (2004). Gezondheidsenquête door middel van interview, deel 5, medische consumptie, gebruik van geneesmiddelen. IPH/EPI reports, nummer 2006 (35), 649-787. Verkregen op 20 maart 2011, via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/table04.htm
§ Beekman, A.T., de Beurs, E., van Balkom, A.J., Deeg, D.J., van Dyck, R. & van Tilburg, W. (2000). Anxiety and depression in later life: Co-occurrence and communality of risk factors. American Journal of Psychiatry, 157(1), 89-95.
§ Benca, R.M. (2005). Diagnosis and treatment of chronic insomnia: a review. Psychiatric Services, 56(3), 332-43.
§ Bentley, K.J., Farmer, R.L., Phillips, M. (1991). Student knowledge of and attitudes toward psychotropic drugs. Journal of Social Work Education, 27, 3.
§ Black, W. & Almeida, O. (2004). A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. International Psychogeriatrics Association, 16, 295–315.
§ Bruggeman, R.T., van Laar, T., Leenders, K.L. (2003). Het werkingsmechanisme van atypische antipsychotica. Tijdschrift voor neurologie en neurochirurgie, 104 (2), 105-12.
§ Buckley, N.A. & Sanders, P. (2000). Cardiovascular adverse effects of antipsychotic drugs. Drugs Safety, 23, 215–228.
§ Buntinx, F., De Leipeleire, J., Fontaine, O., Ylieff, M. (2002). Qualidem eindrapport 1999-2002, versie 1.1. Verkregen op 20 maart 2011, via http://gbiomed.kuleuven.be/english/dep/50000687/50000695/qualidem/qualidem-report-2005
§ Byrne, K.M., Deane, F.P. & Coombs T. (2005). Nurse's beliefs and knowledge about medications are associated with their difficulties using patient treatment adherence strategies. Journal of Mental Health, 14(5), 513 – 521.
§ Cahn, W., Ramlal, D., Bruggeman, R., De Haan, L., Scheepers, F.E., Van Soest, M.M., Assies, J. & Slooff, C.J. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschrift voor Psychiatrie, 9, 579-91.
§ Claes, S., Casteels, M., Danckaets, M., De Lepeleire, J., Demyttenaere, K., Laekeman, G., Luyten, P., Pattyn, B., Schokkaert, E., Truyts., T. (2010). Het toenemend gebruik van psychofarmaca. Opgehaald 20 augustus, 2010, van http://www.kuleuven.be/metaforum/
§ De Bourdeaudhuij, I. (2009). SPSS voor studenten. Ongepubliceerd werkstuk. Universiteit Gent.
§ De Hert, M., Schreurs, V. & Sweers, K. (2008). Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research, 101, 295–303.
§ De Lepeleire, J., Ylieff, M., Buntinx, F., Bouckaert, F., Steeman, E. & Van Tichelt & K. (2008). Omgaan met dementerenden, aanbevelingen vanuit het Qualidem-project. Antwerpen/Apeldoorn: Garant.
§ Demarest, S., Van der Heyden, J., Gisle, L., Buziarsist, J., Miermans, P.J., Sartor, F., Van Oyen, H., Tafforeau, J. (2001). Gezondheidsenquête door middel van Interview, deel 2 gezondheidstoestand, chronische aandoeningen. IPH/EPI reports, nummer 2002 (22), 81-237. Verkregen op 20 maart 2011, via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/TABLE01.HTM
§ Demotte, R. (2005, November 24). Het doelmatig gebruik van geneesmiddelen bij de behandeling van dementie bij ouderen. Juryrapport consensusvergadering RIZIV. Verkregen op 19 december 2010, via http://www.riziv.be/drug/nl/statistics-scientific-information/consensus/index.htm
§ Drici, M.D. & Prioris S. (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 16(8), 882-90.
§ Dunkin, J.J. & Anderson-Hanley, C. (1998). Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention. Neurology, 51,53-60
§ Dwyer, J.T., Stoulorow, K.A., & Orr, R. (1981). Nutrition knowledge test for high school students. Journal of Nutrition Education, 13, 93-94.
§ Edward, K.L., Rasmussen, B. & Munro, I. (2010). Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes. Archives of Psychiatric Nursing, 24(1), 46-53.
§ Fernandez, L. & Cassagne-Pinel, C. (2001). Benzodiazepine addiction and symptoms of anxiety and depression in elderly subjects. L’Encéphale, 27(5), 459-74.
§ Fossey, J., Ballard, C., Juszczak, E., James, I., Alder, N., Jacoby, R. & Howard, R. (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. British Medical Journal, 332(7544), 756-61.
§ Fretwell, C. & Felce, D. (2007). Staff Knowledge of the Side Effects of Anti-Psychotic Medication. Journal of Applied Research in Intellectual Disabilities, 20, 580–585.
§ Giron, M.S., Forsell, Y., Bernsten, C., Thorslund, M., Winblad, B., Fastbom, J. (2002). Sleep problems in a very old population: drug use and clinical correlates. Journal of Gerontology, 57, 236-40.
§ Glass J., Lanctôt, K.L., Herrmann, N., Sproule, B.A. & Busto, U.E. (2005). Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Brittish Medicat Journal, 19; 331-41.
§ Goodman, L.S. & Gilman, A. (2006). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill.
§ Gorgels, W., Oude Voshaar, R., Mol, A., Breteler, M., van de Lisdonk, E. & Zitman, E. (2001, 14 juni). Het langdurig gebruik van benzodiazepinen. Nederlands Tijdschrift voor Geneeskunde, 145(28), 1324-6.
§ Green, A.I., Patel, J.K., Goisman, R.M., Allison, D.B. & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: need for action. General Hospiral Psychiatry, 22(4), 224-35.
§ Heijnen, G. en Meeder, S. (1999) Toetsen en ICT in het hoger onderwijs, Utrecht, Stichting Surf.
§ Holton, A., Riley, P. & Tyrer, P. (1992). Factors predicting long-term outcome after chronic benzodiazepine therapy. Journal of Affective Disorders, 24(4), 245-52.
§ Holtzer, R., Tang, M. X., Devanand, D. P., Albert, S. M., Wegesin, D. J., Marder, K., Bell, K., Albert, M., Brandt, J. & Stern, Y. (2003) Psychopathological features in Alzheimer’s disease: course and relationship with cognitive status. Journal of American Geriatric Society, 51, 953-60.
§ Jano, E., Johnson, M., Chen, H. & Aparasus R.R. (2008). Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Current Medical Research and Opinion, 24(3), 709-16.
§ Kamble, P., Chen, H., Sherer, J. & Aparasu, R.R. (2008). Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 6(4), 187-97.
§ Lader, M., Tylee, A. & Donoghue, J. (2009). Withdrawing benzodiazepines in primary care. CNS Drugs, 23(1), 19-34.
§ Laroche, M.L., Charmes, J.P., Nouaille, Y., Fourrier, A., Merle, L. (2006). Impact of hospitalisation in an acute medical geriatric unit on potentially inappropriate medication use. Drugs and Aging, 23, 49-59.
§ Lee, P.E., Sykora, K., Gill, S.S., Mamdani, M., Marras, C., Anderson, G., Shulman, K.I., Stukel, T., Normand, S.L., Rochon, P.A. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of American Geriatric Society 53(8), 1374-9.
§ Lindesay, J., Matthews, R. & Jagger, C. (2003). Factors associated with antipsychotic drug use in residential care: Changes between 1990 and 1997. International Journal of Geriatric Psychiatry,18, 511–519.
§ Liperoti, R., Mor, V., Lapane, K.L., Pedone, C., Gambassi, G. & Bernabei, R. (2003). The use of atypical antipsychotics in nursing homes. Journal of Clinical Psychiatry, 64, 1106-12.
§ Liperoti, R., Onder, G., Landi, F., Lapane, K.L., Mor, V., Bernabei, R., Gambassi, G. (2009). All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. Journal of Clinical Psychiatry, 70(10), 1340-7
§ Lövheim, H., Sandman, P.O., Kallin, K., Karlsson, S. & Gustafson, Y. (2006). Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. International Psychogeriatric Association, 18(4), 713-26.
§ Lynn, M.R. (1986). Determination and quantification of content validity. Nursing Research, 35(6), 382-385.
§ Madhusoodanan, S. & Bogunovic, O.J. (2004). Safety of benzodiazepines in the geriatric population. Expert Opinion on drug safety, 3(5), 485-93.
§ Mancuso, C.E., Tanzi, M.G. & Gabay, M. (2004). Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy, 24(9), 1177-85
§ Manias, E., & Bullock, S. (2002). The educational preparation of undergraduate nursing students in pharmacology: Clinical nurses’ perceptions and experiences of graduate nurses’ medication knowledge. International Journal of Nursing Studies, 39, 773 – 784.
§ Marcantonio, E.R., Juarez, G., Goldman, L., Mangione, C.M., Ludwig, L.E., Lind, L., Katz, N., Cook, E.F., Orav, E.J. & Lee, T.H. (1994, 16 november). The relationship of postoperative delirium with psychoactive medications. Journal of the American Medical Association, 272(19), 1518-22.
§ Markowitz, J.S., Brown, C.S. & Moore, T.R. (1999) Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. The Annals of Pharmacotherapics, 33, 73-85
§ Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A. & Lichstein, K. L. (2006, 1 november). Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep, 29(11), 1398-414.
§ Neutel, C.I. (1995). Risk of traffic accident injury after a prescription for a benzodiazepine. Annals of Epidemiology, 5(3), 239-44.
§ National Institute for Health and Clinical Excellence (2006) Dementia, supporting people with dementia and their carers in health and social care. CG 42. London: National Institute for Health and Clinical Excellence. Verkregen op 20 februari 2011, via http://www.nice.org.uk/nicemedia/live/10998/30318/30318.pdf
§ Paterniti, S., Dufouil, C. & Alpérovitch, A. (2002). Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. Journal of Clinical Psychopharmacology, 22(3), 285-93.
§ Peck, S. (2005). Clinical guideline for the care and treatment of older people with delirium in a general hospital setting (2nd edition). Verkregen op 12 mei 2011, via http://www.iow.nhs.uk/uploads/Mental/Older/Delirium%20Guideline.pdf
§ Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia- Unzueta, M. T., Ramirez-Bonilla, M. L. & Gonzalez- Blanch, C. (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, firstepisode psychosis patients treated with haloperidol, olanzapine, or risperidone. The Journal of Clinical Psychiatry, 68(11), 1733–1740.
§ Polit, D.F. & Beck, C.H. (2008). Essentials of Nursing Research: Methods, appraisal, and utilization. Philadelphia: Lippincott.
§ Restifo, S., Lemon, V. & Waters, F. (2011)/ Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units. Australasian Psychiatry, 19(1), 59-63.
§ Ruschena, D., Mullen, P.E., Palmer, S., Burgess, P., Cordner, S.M. & Drummer, O.H. (2003). Choking deaths: the role of antipsychotic medication. Brittish Journal of Psychiatry, 183, 446-50.
§ Sabbe, E., Van de Poele, L., & De Cock, K. (2007). Multiple choice: een handleiding bij de ontwikkeling en kwaliteitscontrole van meerkeuze examens in het universitair onderwijs. Ongepubliceerd werkstuk. Universiteit Gent.
§ Scheepers-Hoeks, A.M.J.W., Wessels-Basten, S.J.W., Scherders, M.J.W.T., Bravenboer, B., Loonen, A.J.M., Kleppe, R.T., Grouls, R.J.E. (2008). Schizofrenie en antipsychotica: samenhang met het metabool syndroom. Tijdschrift voor psychiatrie, 50, 645-564.
§ Shorr, R.I., & Robin, D.W. (1994). Rational use of benzodiazepines in the elderly. Drugs & Aging. 4(1), 9-20.
§ Siddiqi, N., House, A.O. & Holmes, J.D. (2006). Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age & Ageing, 35(4), 350-364.
§ Sink, K.M., Holden, K.F. & Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Journal of American Medical Association, 293, 596-608.
§ Streiner, D. L., & Norman, G. R. (2003). Health measurement scales: A practical guide to their development and use (3rd ed.). New York: Oxford University Press.
§ Taylor, D., Paton, C.& Kapur, S. (2009). Prescribing Guidelines, 10th edition. Londen: Informa Healthcare.
§ Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M. & Fleischhacker,W.W. (2007). Metabolic side effects of antipsychotic medication. International Journal Of Clinical Practice, 61(8), 1356–1370.
§ U.S. Food and Drug Administration (2010). FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. Verkregen op 20 februari 2011, via www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html
§ Snowdon, J., Day, S. & Baker, W. (2006).Current use of psychotropic medication in nursing homes. International Psychogeriatrics, 18, 241–250.
§ Steeman E., Braes T., De Bal N., Godderis J., Joosten E., Marvellie M., Milisen K., Van Wesenbeeck A., Vandenberghe J. & Vlaemynck J. (2004). Ontwarring van verwardheid. Mechelen: Kluwer.
§ Steinberg, M., Shao, H., Zandi, P., Lyketsos, C.G., Welsh-Bohmer, K.A., Norton, M.C., Breitner, J.C., Steffens, D.C. & Tschanz, J.T. (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23(2), 170-7.
§ Tschanz, J.T., Corcoran, C., Skoog, I., Khachaturian, A.S., Herrick, J. & Hayden, K.M. (2004). Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology, 62, 1156-62.
§ Van der Heyden, J., Gisle, L., Demarest, S., Drieskens, S., Hesse, E., Tafforeau, J. (2008). Gezondheidsenquête door middel van interview, deel 3, medische consumptie, gebruik van geneesmiddelen. IPH/EPI reports, nummer 2008, 517-604. Verkregen op 15 maart 2011,via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/table08.htm
§ Vander Stichele, R.H., Van de Voorde, C., Elseviers, M., Verrue, C., Soenen, K. & Smet, M. (2006). Geneesmiddelengebruik in de Belgische rusthuizen en rust- en verzorgingstehuizen. Health Services Research (HSR). Brussel: Federaal Kenniscentrum voor de gezondheidszorg (KCE); 2006. KCE reports 47 A.
§ Vander Stichele RH, Van de Voorde C, Elseviers M, Verrue C, Soenen K, Smet M, et al. (2006). Medication use in rest and nursing homes in Belgium. Health Services Research (HSR). Brussels: Belgian Health Care Knowledge Centre (KCE); 2006. KCE reports 47 C
§ Verdoux, H., Lagnaoui, R. & Begaud, B. (2005). Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiologic studies. Psycholigical Medicine, 35, 307– 15.
§ Wang, P., Bohn, R., Glynn, R., Mogun, H. & Avorn, J. (2001). Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Americal Journal of Psychiatry, 158, 892– 8.
§ Warie, H., Petrovic, M., Somers, A., Mariman, A., Robays, H. & Pevernagie, D. (2003). The use of hypnosedative drugs in a university hospital setting. Acta Clinica Belgica, 58(4), 225-32.
§ Wood-Mitchell, A., James, I.A., Waterworth, A., Swann, A. & Ballard, C. (2008) Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing, Oxford Journals, 37(5), 547-52.
§ Wolkove, N., Elkholy, O., Baltzan, M., & Palayew, M. (2007). Sleep and aging: Management of sleep disorders in older people. Canadian Medical Association Journal, 176(10), 1449-54.
§ Wren, P., Frizzell, L. A., Keltner, N. L. & Wright, A.V. (2003). Three potentially fatal adverse effects of psychotropic medications. Perspectives in Psychiatric Care, 39(2), 75-81.
§ Zandstra, S.M., van Rijswijk, E. & Rijnders, C.A. (2004). Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. The Journal of Family Practice, 21, 266-9.§ Alexander, C.M., Landsman, P.B., Teutsch, S.M. & Haffner, S.M. (2003). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52, 1210–1214.
§ Alexander, H. & Glassman, M.D. (2005). Schizophrenia, antipsychotic drugs, and cardiovascular disease. Journal of Clinical Psychiatry, 66, 5–10.
§ Alexopoulos, G.S., Streim, J., Carpenter, D. & Docherty, J.P. (2004). Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. Journal of Clinical Psychiatry, 65, 5-99.
§ Alvarez-Jiménez, M., González-Blanch, C., Cespo-Facorro, B., Hetrick, S., Rodríguez-Sánchez, J.M., Pérez-Iglesias, R. & Vázquez-Barquero, J.L. (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs, 22(7), 547-62.
§ Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18, 249-55
§ Ballard, C., Creese, B., Corbett, A. & Aarsland, D. (2011, januari). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10(1), 35-43.
§ Bayingana, K., Demarest, S., Gisle, L., Hesse, E., Miermans, P.J., Tafforeau, J., Van der Heyden, J. (2004). Gezondheidsenquête door middel van interview, deel 5, medische consumptie, gebruik van geneesmiddelen. IPH/EPI reports, nummer 2006 (35), 649-787. Verkregen op 20 maart 2011, via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/table04.htm
§ Beekman, A.T., de Beurs, E., van Balkom, A.J., Deeg, D.J., van Dyck, R. & van Tilburg, W. (2000). Anxiety and depression in later life: Co-occurrence and communality of risk factors. American Journal of Psychiatry, 157(1), 89-95.
§ Benca, R.M. (2005). Diagnosis and treatment of chronic insomnia: a review. Psychiatric Services, 56(3), 332-43.
§ Bentley, K.J., Farmer, R.L., Phillips, M. (1991). Student knowledge of and attitudes toward psychotropic drugs. Journal of Social Work Education, 27, 3.
§ Black, W. & Almeida, O. (2004). A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. International Psychogeriatrics Association, 16, 295–315.
§ Bruggeman, R.T., van Laar, T., Leenders, K.L. (2003). Het werkingsmechanisme van atypische antipsychotica. Tijdschrift voor neurologie en neurochirurgie, 104 (2), 105-12.
§ Buckley, N.A. & Sanders, P. (2000). Cardiovascular adverse effects of antipsychotic drugs. Drugs Safety, 23, 215–228.
§ Buntinx, F., De Leipeleire, J., Fontaine, O., Ylieff, M. (2002). Qualidem eindrapport 1999-2002, versie 1.1. Verkregen op 20 maart 2011, via http://gbiomed.kuleuven.be/english/dep/50000687/50000695/qualidem/qualidem-report-2005
§ Byrne, K.M., Deane, F.P. & Coombs T. (2005). Nurse's beliefs and knowledge about medications are associated with their difficulties using patient treatment adherence strategies. Journal of Mental Health, 14(5), 513 – 521.
§ Cahn, W., Ramlal, D., Bruggeman, R., De Haan, L., Scheepers, F.E., Van Soest, M.M., Assies, J. & Slooff, C.J. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschrift voor Psychiatrie, 9, 579-91.
§ Claes, S., Casteels, M., Danckaets, M., De Lepeleire, J., Demyttenaere, K., Laekeman, G., Luyten, P., Pattyn, B., Schokkaert, E., Truyts., T. (2010). Het toenemend gebruik van psychofarmaca. Opgehaald 20 augustus, 2010, van http://www.kuleuven.be/metaforum/
§ De Bourdeaudhuij, I. (2009). SPSS voor studenten. Ongepubliceerd werkstuk. Universiteit Gent.
§ De Hert, M., Schreurs, V. & Sweers, K. (2008). Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research, 101, 295–303.
§ De Lepeleire, J., Ylieff, M., Buntinx, F., Bouckaert, F., Steeman, E. & Van Tichelt & K. (2008). Omgaan met dementerenden, aanbevelingen vanuit het Qualidem-project. Antwerpen/Apeldoorn: Garant.
§ Demarest, S., Van der Heyden, J., Gisle, L., Buziarsist, J., Miermans, P.J., Sartor, F., Van Oyen, H., Tafforeau, J. (2001). Gezondheidsenquête door middel van Interview, deel 2 gezondheidstoestand, chronische aandoeningen. IPH/EPI reports, nummer 2002 (22), 81-237. Verkregen op 20 maart 2011, via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/TABLE01.HTM
§ Demotte, R. (2005, November 24). Het doelmatig gebruik van geneesmiddelen bij de behandeling van dementie bij ouderen. Juryrapport consensusvergadering RIZIV. Verkregen op 19 december 2010, via http://www.riziv.be/drug/nl/statistics-scientific-information/consensus/index.htm
§ Drici, M.D. & Prioris S. (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 16(8), 882-90.
§ Dunkin, J.J. & Anderson-Hanley, C. (1998). Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention. Neurology, 51,53-60
§ Dwyer, J.T., Stoulorow, K.A., & Orr, R. (1981). Nutrition knowledge test for high school students. Journal of Nutrition Education, 13, 93-94.
§ Edward, K.L., Rasmussen, B. & Munro, I. (2010). Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes. Archives of Psychiatric Nursing, 24(1), 46-53.
§ Fernandez, L. & Cassagne-Pinel, C. (2001). Benzodiazepine addiction and symptoms of anxiety and depression in elderly subjects. L’Encéphale, 27(5), 459-74.
§ Fossey, J., Ballard, C., Juszczak, E., James, I., Alder, N., Jacoby, R. & Howard, R. (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. British Medical Journal, 332(7544), 756-61.
§ Fretwell, C. & Felce, D. (2007). Staff Knowledge of the Side Effects of Anti-Psychotic Medication. Journal of Applied Research in Intellectual Disabilities, 20, 580–585.
§ Giron, M.S., Forsell, Y., Bernsten, C., Thorslund, M., Winblad, B., Fastbom, J. (2002). Sleep problems in a very old population: drug use and clinical correlates. Journal of Gerontology, 57, 236-40.
§ Glass J., Lanctôt, K.L., Herrmann, N., Sproule, B.A. & Busto, U.E. (2005). Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Brittish Medicat Journal, 19; 331-41.
§ Goodman, L.S. & Gilman, A. (2006). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill.
§ Gorgels, W., Oude Voshaar, R., Mol, A., Breteler, M., van de Lisdonk, E. & Zitman, E. (2001, 14 juni). Het langdurig gebruik van benzodiazepinen. Nederlands Tijdschrift voor Geneeskunde, 145(28), 1324-6.
§ Green, A.I., Patel, J.K., Goisman, R.M., Allison, D.B. & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: need for action. General Hospiral Psychiatry, 22(4), 224-35.
§ Heijnen, G. en Meeder, S. (1999) Toetsen en ICT in het hoger onderwijs, Utrecht, Stichting Surf.
§ Holton, A., Riley, P. & Tyrer, P. (1992). Factors predicting long-term outcome after chronic benzodiazepine therapy. Journal of Affective Disorders, 24(4), 245-52.
§ Holtzer, R., Tang, M. X., Devanand, D. P., Albert, S. M., Wegesin, D. J., Marder, K., Bell, K., Albert, M., Brandt, J. & Stern, Y. (2003) Psychopathological features in Alzheimer’s disease: course and relationship with cognitive status. Journal of American Geriatric Society, 51, 953-60.
§ Jano, E., Johnson, M., Chen, H. & Aparasus R.R. (2008). Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Current Medical Research and Opinion, 24(3), 709-16.
§ Kamble, P., Chen, H., Sherer, J. & Aparasu, R.R. (2008). Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 6(4), 187-97.
§ Lader, M., Tylee, A. & Donoghue, J. (2009). Withdrawing benzodiazepines in primary care. CNS Drugs, 23(1), 19-34.
§ Laroche, M.L., Charmes, J.P., Nouaille, Y., Fourrier, A., Merle, L. (2006). Impact of hospitalisation in an acute medical geriatric unit on potentially inappropriate medication use. Drugs and Aging, 23, 49-59.
§ Lee, P.E., Sykora, K., Gill, S.S., Mamdani, M., Marras, C., Anderson, G., Shulman, K.I., Stukel, T., Normand, S.L., Rochon, P.A. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of American Geriatric Society 53(8), 1374-9.
§ Lindesay, J., Matthews, R. & Jagger, C. (2003). Factors associated with antipsychotic drug use in residential care: Changes between 1990 and 1997. International Journal of Geriatric Psychiatry,18, 511–519.
§ Liperoti, R., Mor, V., Lapane, K.L., Pedone, C., Gambassi, G. & Bernabei, R. (2003). The use of atypical antipsychotics in nursing homes. Journal of Clinical Psychiatry, 64, 1106-12.
§ Liperoti, R., Onder, G., Landi, F., Lapane, K.L., Mor, V., Bernabei, R., Gambassi, G. (2009). All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. Journal of Clinical Psychiatry, 70(10), 1340-7
§ Lövheim, H., Sandman, P.O., Kallin, K., Karlsson, S. & Gustafson, Y. (2006). Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. International Psychogeriatric Association, 18(4), 713-26.
§ Lynn, M.R. (1986). Determination and quantification of content validity. Nursing Research, 35(6), 382-385.
§ Madhusoodanan, S. & Bogunovic, O.J. (2004). Safety of benzodiazepines in the geriatric population. Expert Opinion on drug safety, 3(5), 485-93.
§ Mancuso, C.E., Tanzi, M.G. & Gabay, M. (2004). Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy, 24(9), 1177-85
§ Manias, E., & Bullock, S. (2002). The educational preparation of undergraduate nursing students in pharmacology: Clinical nurses’ perceptions and experiences of graduate nurses’ medication knowledge. International Journal of Nursing Studies, 39, 773 – 784.
§ Marcantonio, E.R., Juarez, G., Goldman, L., Mangione, C.M., Ludwig, L.E., Lind, L., Katz, N., Cook, E.F., Orav, E.J. & Lee, T.H. (1994, 16 november). The relationship of postoperative delirium with psychoactive medications. Journal of the American Medical Association, 272(19), 1518-22.
§ Markowitz, J.S., Brown, C.S. & Moore, T.R. (1999) Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. The Annals of Pharmacotherapics, 33, 73-85
§ Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A. & Lichstein, K. L. (2006, 1 november). Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep, 29(11), 1398-414.
§ Neutel, C.I. (1995). Risk of traffic accident injury after a prescription for a benzodiazepine. Annals of Epidemiology, 5(3), 239-44.
§ National Institute for Health and Clinical Excellence (2006) Dementia, supporting people with dementia and their carers in health and social care. CG 42. London: National Institute for Health and Clinical Excellence. Verkregen op 20 februari 2011, via http://www.nice.org.uk/nicemedia/live/10998/30318/30318.pdf
§ Paterniti, S., Dufouil, C. & Alpérovitch, A. (2002). Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. Journal of Clinical Psychopharmacology, 22(3), 285-93.
§ Peck, S. (2005). Clinical guideline for the care and treatment of older people with delirium in a general hospital setting (2nd edition). Verkregen op 12 mei 2011, via http://www.iow.nhs.uk/uploads/Mental/Older/Delirium%20Guideline.pdf
§ Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia- Unzueta, M. T., Ramirez-Bonilla, M. L. & Gonzalez- Blanch, C. (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, firstepisode psychosis patients treated with haloperidol, olanzapine, or risperidone. The Journal of Clinical Psychiatry, 68(11), 1733–1740.
§ Polit, D.F. & Beck, C.H. (2008). Essentials of Nursing Research: Methods, appraisal, and utilization. Philadelphia: Lippincott.
§ Restifo, S., Lemon, V. & Waters, F. (2011)/ Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units. Australasian Psychiatry, 19(1), 59-63.
§ Ruschena, D., Mullen, P.E., Palmer, S., Burgess, P., Cordner, S.M. & Drummer, O.H. (2003). Choking deaths: the role of antipsychotic medication. Brittish Journal of Psychiatry, 183, 446-50.
§ Sabbe, E., Van de Poele, L., & De Cock, K. (2007). Multiple choice: een handleiding bij de ontwikkeling en kwaliteitscontrole van meerkeuze examens in het universitair onderwijs. Ongepubliceerd werkstuk. Universiteit Gent.
§ Scheepers-Hoeks, A.M.J.W., Wessels-Basten, S.J.W., Scherders, M.J.W.T., Bravenboer, B., Loonen, A.J.M., Kleppe, R.T., Grouls, R.J.E. (2008). Schizofrenie en antipsychotica: samenhang met het metabool syndroom. Tijdschrift voor psychiatrie, 50, 645-564.
§ Shorr, R.I., & Robin, D.W. (1994). Rational use of benzodiazepines in the elderly. Drugs & Aging. 4(1), 9-20.
§ Siddiqi, N., House, A.O. & Holmes, J.D. (2006). Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age & Ageing, 35(4), 350-364.
§ Sink, K.M., Holden, K.F. & Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Journal of American Medical Association, 293, 596-608.
§ Streiner, D. L., & Norman, G. R. (2003). Health measurement scales: A practical guide to their development and use (3rd ed.). New York: Oxford University Press.
§ Taylor, D., Paton, C.& Kapur, S. (2009). Prescribing Guidelines, 10th edition. Londen: Informa Healthcare.
§ Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M. & Fleischhacker,W.W. (2007). Metabolic side effects of antipsychotic medication. International Journal Of Clinical Practice, 61(8), 1356–1370.
§ U.S. Food and Drug Administration (2010). FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. Verkregen op 20 februari 2011, via www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html
§ Snowdon, J., Day, S. & Baker, W. (2006).Current use of psychotropic medication in nursing homes. International Psychogeriatrics, 18, 241–250.
§ Steeman E., Braes T., De Bal N., Godderis J., Joosten E., Marvellie M., Milisen K., Van Wesenbeeck A., Vandenberghe J. & Vlaemynck J. (2004). Ontwarring van verwardheid. Mechelen: Kluwer.
§ Steinberg, M., Shao, H., Zandi, P., Lyketsos, C.G., Welsh-Bohmer, K.A., Norton, M.C., Breitner, J.C., Steffens, D.C. & Tschanz, J.T. (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23(2), 170-7.
§ Tschanz, J.T., Corcoran, C., Skoog, I., Khachaturian, A.S., Herrick, J. & Hayden, K.M. (2004). Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology, 62, 1156-62.
§ Van der Heyden, J., Gisle, L., Demarest, S., Drieskens, S., Hesse, E., Tafforeau, J. (2008). Gezondheidsenquête door middel van interview, deel 3, medische consumptie, gebruik van geneesmiddelen. IPH/EPI reports, nummer 2008, 517-604. Verkregen op 15 maart 2011,via http://www.iph.fgov.be/epidemio/epinl/crospnl/hisnl/table08.htm
§ Vander Stichele, R.H., Van de Voorde, C., Elseviers, M., Verrue, C., Soenen, K. & Smet, M. (2006). Geneesmiddelengebruik in de Belgische rusthuizen en rust- en verzorgingstehuizen. Health Services Research (HSR). Brussel: Federaal Kenniscentrum voor de gezondheidszorg (KCE); 2006. KCE reports 47 A.
§ Vander Stichele RH, Van de Voorde C, Elseviers M, Verrue C, Soenen K, Smet M, et al. (2006). Medication use in rest and nursing homes in Belgium. Health Services Research (HSR). Brussels: Belgian Health Care Knowledge Centre (KCE); 2006. KCE reports 47 C
§ Verdoux, H., Lagnaoui, R. & Begaud, B. (2005). Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiologic studies. Psycholigical Medicine, 35, 307– 15.
§ Wang, P., Bohn, R., Glynn, R., Mogun, H. & Avorn, J. (2001). Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Americal Journal of Psychiatry, 158, 892– 8.
§ Warie, H., Petrovic, M., Somers, A., Mariman, A., Robays, H. & Pevernagie, D. (2003). The use of hypnosedative drugs in a university hospital setting. Acta Clinica Belgica, 58(4), 225-32.
§ Wood-Mitchell, A., James, I.A., Waterworth, A., Swann, A. & Ballard, C. (2008) Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing, Oxford Journals, 37(5), 547-52.
§ Wolkove, N., Elkholy, O., Baltzan, M., & Palayew, M. (2007). Sleep and aging: Management of sleep disorders in older people. Canadian Medical Association Journal, 176(10), 1449-54.
§ Wren, P., Frizzell, L. A., Keltner, N. L. & Wright, A.V. (2003). Three potentially fatal adverse effects of psychotropic medications. Perspectives in Psychiatric Care, 39(2), 75-81.
§ Zandstra, S.M., van Rijswijk, E. & Rijnders, C.A. (2004). Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. The Journal of Family Practice, 21, 266-9.